miRNA Expression in Fibroblastic Foci within Idiopathic Pulmonary Fibrosis Lungs Reveals Novel Disease-Relevant Pathways.


Journal

The American journal of pathology
ISSN: 1525-2191
Titre abrégé: Am J Pathol
Pays: United States
ID NLM: 0370502

Informations de publication

Date de publication:
04 2023
Historique:
received: 03 10 2022
revised: 19 12 2022
accepted: 28 12 2022
medline: 4 4 2023
pubmed: 24 1 2023
entrez: 23 1 2023
Statut: ppublish

Résumé

miRNAs are 22 nucleotides long and belong to a class of noncoding RNAs that plays an important role in regulating gene expression at a post-transcriptional level. Studies show aberrant levels of miRNAs to be associated with profibrotic processes in idiopathic pulmonary fibrosis (IPF). However, most of these studies used whole IPF tissue or in vitro monocultures in which fibrosis was artificially induced. The current study used laser microdissection to collect fibroblastic foci (FF), the key pathologic lesion in IPF, isolated miRNAs, and compared their expression levels with those found in whole IPF lung tissue and/or in vitro cultured fibroblast from IPF or normal lungs. Sequencing libraries were generated, and data generated were bioinformatically analyzed. A total of 18 miRNAs were significantly overexpressed in FF tissue when compared with whole IPF tissue. Of those, 15 were unique to FF. Comparison of FF with cultured IPF fibroblasts also revealed differences in miRNA composition that impacted several signaling pathways. The miRNA composition of FF is both overlapping and distinct from that of whole IPF tissue or cultured IPF fibroblasts and highlights the importance of characterizing FF biology as a phenotypically and functionally discrete tissue microenvironment.

Identifiants

pubmed: 36690076
pii: S0002-9440(23)00032-9
doi: 10.1016/j.ajpath.2022.12.015
pii:
doi:

Substances chimiques

MicroRNAs 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

417-429

Subventions

Organisme : Medical Research Council
ID : G0900535
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K001949/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R023026/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 206103/Z/17/Z
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom

Informations de copyright

Copyright © 2023 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Auteurs

Laura Sabater (L)

Newcastle Fibrosis Research Group, Biosciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.

Jean B Gossart (JB)

Newcastle Fibrosis Research Group, Biosciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.

Inmaculada Hernandez (I)

Computational Epigenomics Laboratory, Biosciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.

Daniel Rico (D)

Computational Epigenomics Laboratory, Biosciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.

Andy Blanchard (A)

GlaxoSmithKline Medicines Research Centre, Stevenage, United Kingdom.

Lee A Borthwick (LA)

Newcastle Fibrosis Research Group, Biosciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.

Andrew J Fisher (AJ)

Institute of Transplantation, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.

Joaquim Majo (J)

Institute of Transplantation, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.

Kasim Jiwa (K)

Institute of Transplantation, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.

Amy Collins (A)

Newcastle Fibrosis Research Group, Biosciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom; FibroFind Ltd, FibroFind Laboratories, Medical School, Newcastle University, Newcastle upon Tyne, United Kingdom.

Giuseppe Abbate (G)

FibroFind Ltd, FibroFind Laboratories, Medical School, Newcastle University, Newcastle upon Tyne, United Kingdom.

Fiona Oakley (F)

Newcastle Fibrosis Research Group, Biosciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom; FibroFind Ltd, FibroFind Laboratories, Medical School, Newcastle University, Newcastle upon Tyne, United Kingdom.

Derek A Mann (DA)

Newcastle Fibrosis Research Group, Biosciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom; FibroFind Ltd, FibroFind Laboratories, Medical School, Newcastle University, Newcastle upon Tyne, United Kingdom.

Jelena Mann (J)

Newcastle Fibrosis Research Group, Biosciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom; FibroFind Ltd, FibroFind Laboratories, Medical School, Newcastle University, Newcastle upon Tyne, United Kingdom. Electronic address: jelena.mann@ncl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH